Clavulanic acid, sulbactam, and tazobactam are inhibitors of a variety of plasmid-mediated Il-lactamases. However, inhibition data for these three inhibitors with a wide range of different plasmid-mediated P-lactamases have not yet been compared under the same experimental conditions. A number of groups have inferred that clavulanic acid inhibits extended-spectrum TEM and SHV P-lactamases, but inhibition data have rarely been published. In this study, the 50%o inhibitory concentrations of these three ,-lactamase inhibitors for 35 plasmid-mediated P-lactamases have been determined. Of these 35 P-lactamases, 20 were extendedspectrum TEM-or SHV-derived I-lactamases. The other 15 enzymes were conventional-spectrum P-lactamases such as TEM-1 and SHV-1. Clavulanic acid was a more potent inhibitor than sulbactam for 32 of the 35 plasmid-mediated I-lactamases tested. In particular, clavulanic acid was 60 and 580 times more potent than sulbactam against TEM-1 and SHV-1, respectively, currently the two most clinically prevalent gram-negative plasmid-mediated I-lactamases. Statistical analysis of the data of the 50% inhibitory concentrations showed that clavulanic acid was 20 times more active overall than sulbactam against the conventional-spectrum enzymes. In addition, clavulanic acid was 14 times more potent than sulbactam at inhibiting the extendedspectrum enzymes. Tazobactam also showed significantly greater activity than sulbactam against the two groups of P-lactamases. There were no significant differences between the overall activities of tazobactam and clavulanic acid against the extended-spectrum TEM and SHV enzymes and conventional-spectrum enzymes, although differences in their inhibition profiles were observed.
I-lactamases are plasmid-encoded or chromosomally encoded bacterial enzymes which hydrolyze 3-lactam antibiotics.
Plasmid-mediated ,-lactamases can transfer rapidly between bacterial genera and consequently pose a major threat to the successful use of ,-lactam agents. More than 60 different types of plasmid-encoded ,-lactamases have been characterized, and for the purpose of this work, the enzymes have been classified as either conventional-spectrum or TEM-and SHVderived extended-spectrum enzymes. The conventional-spectrum ,-lactamases are from Bush groups 2a, 2b, 2c, and 2d, and extended-spectrum TEM and SHV enzymes are all from group 2b' (4) .
The conventional-spectrum enzymes include enzymes such as TEM-1 and SHV-1, which do not confer resistance to cephalosporins such as ceftazidime and cefotaxime. A recent survey of 802 gram-negative clinical isolates showed that TEM-1 and SHV-1 were responsible for mediating P-lactam resistance in 17% of clinical isolates (37) . Other conventionalspectrum enzymes which are often found in clinical isolates include the OXA and PSE P-lactamases (1) . The most common conventional-spectrum plasmid-mediated 13-lactamase found in gram-positive bacteria is the penicillinase produced by the majority of Staphylococcus aureus clinical isolates (26) .
Most of the extended-spectrum plasmid-mediated ,B-lactamases are derived from the TEM and SHV ,B-lactamase genes and confer transferable resistance to the newer broad-spectrum cephalosporins such as cefotaxime and ceftazidime. So far, at least 25 to 30 different extended-spectrum ,-lactamases have been reported, and none of the enzymes appear to dominate the clinical situation worldwide. Therefore, a broad selection of extended-spectrum 1-lactamases must be examined when assessing the activities of antimicrobial agents against such enzymes. The clinical prevalence of extendedspectrum ,B-lactamases in certain areas is increasing (35) and consequently compromises the effectiveness of the newer cephalosporins (17) .
Combinations of ,B-lactam antibiotics and ,-lactamase inhibitors have proved successful at treating infections caused by bacteria producing 13-lactamases (22) . The potency of such combinations continues to be largely assessed by susceptibility testing (2) . Such studies have suggested that clavulanic acid and other P-lactamase inhibitors differentially inhibit various types of plasmid-mediated 3-lactamases (15, 16, 19) . However, the activity of a particular combination against clinical isolates is affected by the interplay of many different factors which are discussed in detail by Thomson et al. (36) . One major component which affects the overall antibacterial activity of a ,-lactam-3-lactamase inhibitor combination is the susceptibility of the 3-lactamase to the inhibitor, and it is this component which has been addressed in our study. As there are now many different types of plasmid-mediated 3-lactamase, any assessment of the potency of different ,B-lactamase inhibitors must be performed on a broad range of 3-lactamases. Therefore, this paper reports the results of a comprehensive study which has examined the ,B-lactamase inhibitory activities of clavulanic acid, sulbactam, and tazobactam against 35 isolated plasmidmediated ,-lactamases. Twenty of the enzymes were extendedspectrum ,B-lactamases, and the remainder were conventionalspectrum plasmid-mediated ,B-lactamases.
MATERIALS AND METHODS
Antibiotics. Sulbactam was supplied by Pfizer Central Research, and tazobactam was obtained from Lederle Laboratories. Clavulanic acid was prepared in our laboratories. Strains and plasmids. The Escherichia coli transconjugant strains used in this study are listed in Table 1 . These strains were selected because they produced high levels of plasmidmediated P-lactamase. Enzymes A and B were obtained from TEM-1 by in vitro spontaneous mutation; in the same way, enzymes C and D were derived from TEM-2 and enzyme E was derived from PSE-4 (27) . TEM-E2, TEM-El, CAZ-lo, and TEM-E4 have pIs similar to those of enzymes A, B, C, and D, respectively (27) . However, isoelectric focusing data in isolation are not sufficient to assess whether two TEM ,-lactamases with similar pIs are identical (17) . The S. aureus Russell P-lactamase was representative of a typical staphylococcal penicillinase.
Preparation of I8-lactamases. A 1-liter culture (nutrient broth no. 2) of each strain listed in Table 1 was shaken overnight at 37°C. The cells were harvested by centrifugation for 15 min at 6,000 x g. The bacterial pellets were washed in 25 mM sodium phosphate buffer (pH 7), and the centrifugation was repeated. One milliliter of 25 mM sodium phosphate buffer was then added to the final pellet, and the cells were resuspended to give 3 ml of cell suspension, which was disrupted by ultrasound. The cell lysate was cleared by centrifugation for 1 h at 32,000 x g. ,-Lactamase identification. Each 13-lactamase was checked by analytical isoelectric focusing (24) . The enzymes were examined on gels containing a 1:1 ratio of pH 3.5 to pH 10 ampholines and either pH 4 to pH 6 or pH 9 to pH 11 ampholines, depending on the expected pI of the P-lactamase.
The prepared enzymes were focused alongside known 3-lactamase preparations. Each preparation from the E. coli transconjugants was shown to produce only one plasmid-mediated enzyme with a trace amount of the E. coli K-12 chromosomal enzyme. The other strains all produced the single plasmidmediated enzyme. Statistical analysis of the IC50s after log1o transformation was performed by analysis of variance, taking into account the inhibitor, the enzyme, and the two groups of enzymes (conventional-spectrum and extended-spectrum TEM and SHV). Differences in the geometric means were back-transformed to ratios, i.e., relative potencies, of the inhibitors for the different groups of enzymes. The corresponding confidence limits were also determined. Table 2 shows the statistical analysis of at least eight IC50s for four different enzyme-inhibitor interactions. This illustrates that the semiautomated technique described in this paper was acceptably reproducible, with 95% confidence intervals less than 40% of the geometric mean in three of the four enzymeinhibitor interactions. The 95% confidence interval for the fourth combination (clavulanic acid with SHV-5) was within 60% of the geometric mean (Table 2) . Figure 1 
RESULTS
Comparison of the IC50s of 3-lactamase inhibitors against conventional-spectrum P-lactamases. and subsequent discussion of inhibition data refers directly to IC50s (these are tabulated in Table 3 (Table 4 ). The comparison of panels a and b of Fig. 2 clearly demonstrates that tazobactam was more potent than sulbactam. In fact, overall, tazobactam was significantly more potent than sulbactam against this group of enzymes (Table 4) .
Clavulanic acid was also a more potent inhibitor than sulbactam for 19 of the 20 extended-spectrum plasmid-mediated ,B-lactamases (Fig. 3a) . TEM-3 was the only extendedspectrum enzyme against which the activity of sulbactam was comparable to that of clavulanic acid. Statistical analysis of the IC50s shows that, for the 20 enzymes studied, clavulanic acid was 14 times more potent overall than sulbactam (Table 4 ). Figure 3b compares the ,B-lactamase inhibitory activities of clavulanic acid and tazobactam against 20 TEM-and SHVderived extended-spectrum P-lactamases. Both inhibitors were highly active, with IC50s of less than 0.5 FM. In terms of overall potency, the difference between them was not statistically significant. DISCUSSION Detailed kinetic studies have been essential in elucidating the mode of action of mechanism-based P-lactamase inhibitors (5, 21) . However, because of the complexities of such interactions, these studies have been confined to a limited numker of representative 1-lactamases. The proportion of clinical isolates producing plasmid-mediated 1-lactamases is high (37) , and the diversity of these enzymes is also expanding as an inevitable consequence of microbial adaptation (27) . Consequently, from a clinical perspective, it is also essential to investigate the activities of the commercially available ,-lactamase inhibitors against a broad variety of clinically derived ,B-lactamases. Therefore, we have determined the IC50s of the three commercially available 13-lactamase inhibitors for 35 plasmidmediated 3-lactamases. IC50s measure only the activity of a ,-lactamase inhibitor at a fixed time interval after incubation with an enzyme (5 min in this study) . The values obtained are dependent on various kinetic parameters associated with the interactions of both inhibitor and substrate with P-lactamase.
Nevertheless, IC50s do provide the most practical way of evaluating the relative activities of P-lactamase inhibitors for such a large number of enzymes. For these reasons, many other groups have adopted IC50 assays as a means of characterizing 13-lactamases (5, 19, 31) . 100 The semiautomated method for the determination of IC50s proved to be a rapid method for comparing the activities of ,-lactamase inhibitors with an acceptable level of reproducibility.
These results show that clavulanic acid was a more potent inhibitor than sulbactam of both conventional-spectrum and extended-spectrum TEM and SHV enzymes. Jacobs et al. (15) determined the MICs of ampicillin in combination with clavulanic acid and sulbactam for 12 strains of E. coli producing conventional-spectrunm 3-lactamases, and although IC50s and MICs cannot be directly correlated, the MICs do suggest that clavulanic acid had greater activity than did sulbactam against conventional-spectrum enzymes. The only enzyme for which the IC 0 of sulbactam was lower than that of clavulanic acid was OXA-2. However, OXA-2 is of minor clinical significance, being produced by <1% of ampicillin-resistant enterobacterial strains (1). Previously published IC50s (6) also showed that clavulanic acid was a more potent inhibitor than sulbactam of the S. aureus penicillinase, TEM-1, SHV-1, PSE-4, and four extended-spectrum TEM and SHV ,-lactamases (5).
Overall, clavulanic acid and tazobactam were equipotent against both sets of enzymes. However, each inhibitor had a distinct inhibition profile. The IC50s of clavulanic acid for S. aureus Russell, SHV-1, SHV-5, MJ-1, and TEM-5 were 8.1-, 4.7-, 5.9-, 4.8-, and 9.3-fold lower, respectively, than those of tazobactam. In contrast, tazobactam was more active than clavulanic acid against OXA-2 and OXA-5 (137-and 12.3-fold, respectively). Given the reproducibility of the assay and the location of these values at the extremes of the distribution of relative potencies, these differences may be considered significant.
In conclusion, we have reported the use of automated instrumentation to determine the activities of clavulanic acid, sulbactam, and tazobactam against a substantial number of previously reported plasmid-mediated ,B-lactamases. Overall, these IC50s for 35 0-lactamases showed that clavulanic acid and tazobactam were more effective 3-lactamase inhibitors than sulbactam and that clavulanic acid had activities equivalent to those of tazobactam. Although the inhibitory activity of the 3-lactamase inhibitor is only one of the many components which contribute to the overall MIC of a p-lactam-1-lactamase inhibitor combination, this ranking of the activities of ,B-lacta- 
